Company: MDCXW
Filing Date: 2025-08-12
Form Type: 424B3
Source: 0001062993-25-014091
Chunk: 2

Company: Medicus Pharma Ltd.
Filing Date: 2025-08-12
Form: 424B3
Chunk 2
---
.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, anon-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer", "accelerated filer", "smaller reporting company", and "emerging growth company" in Rule 12b-2of the Exchange Act.

| Large accelerated filer | ☐ | Accelerated filer         | ☐ |
| Non-accelerated filer   | ☒ | Smaller reporting company | ☒ |
|                         |   | Emerging growth company   | ☒ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Yes ☐ No ☒ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2of the Exchange Act).
Yes ☐ No ☒ As of August 11, 2025, there were 17,816,266 common shares, no par value, issued and outstanding.

MEDICUS PHARMA LTD. FORM 10-Q FOR THE QUARTER ENDED June 30, 2025 TABLE OF CONTENTS 1

|           |                                                                                                                                              |                       | Page |
|           | Part I.                                                                                                                                      | Financial Information |    1 |
| Item 1.   | Financial Statements                                                                                                                         |                       |    1 |
|           | Condensed Consolidated Balance Sheets as of June 30, 2025 (Unaudited) and December 31, 2024                                                  |                       |    1 |
|           | Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 (Unaudited) |                       |    2 |
|           | Condensed Consolidated Statements of Changes in Shareholders' Equity for the three and six months ended June 30, 2025 and 2024 (Unaudited)   |                       |    3 |
|           | Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and